547 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
REGN Regeneron Pharmaceuticals, Inc. $323.86 $34.88B Downtrend
Article Searches
Orbimed Advisors Llc Buys Regeneron Pharmaceuticals Inc, Amicus Therapeutics Inc, Loxo Oncology ... http://www.gurufocus.com/news/645796/orbimed-advisors-llc-buys-regeneron-pharmaceuticals-inc-amicus-therapeutics-inc-loxo-oncology-inc-sells-incyte-corp-aetna-inc-biogen-inc Feb 23, 2018 - Orbimed Advisors Llc Buys Regeneron Pharmaceuticals Inc, Amicus Therapeutics Inc, Loxo Oncology Inc, Sells Incyte Corp, Aetna Inc, Biogen Inc, Stocks: REGN,LOXO,NVRO,ASMB,DCPH,EVHC,FOLD,RYTM,SCPH,DVA,A, release date:Feb 23, 2018
Some Thoughts On The Continued Negative Media For Regeneron https://seekingalpha.com/article/4150076-thoughts-continued-negative-media-regeneron?source=feed_sector_healthcare Feb 23, 2018 - Regeneron, with a productive pipeline and one of the world's largest-selling drugs in Eylea, has been dropping sharply lately.Just this week, major financial media came out with two negative pieces on
BioMarin (BMRN) Q4 Loss Wider Than Expected, Sales Beat http://www.zacks.com/stock/news/293482/biomarin-bmrn-q4-loss-wider-than-expected-sales-beat?cid=CS-ZC-FT-293482 Feb 23, 2018 - BioMarin (BMRN) reports wider-than-expected loss in the fourth quarter of 2017 but beat estimates for sales on higher product revenues.
Corcept's (CORT) Earnings and Sales Meet Estimates in Q4 http://www.zacks.com/stock/news/293469/corcepts-cort-earnings-and-sales-meet-estimates-in-q4?cid=CS-ZC-FT-293469 Feb 23, 2018 - Corcept (CORT) reports in-line results for the fourth quarter of 2017 and also announces top-line interim phase II data for its pipeline candidate relacorilant.
Undervalued And Attractive: Pick Up Novartis In 2018 https://seekingalpha.com/article/4149081-undervalued-attractive-pick-novartis-2018?source=feed_sector_healthcare Feb 21, 2018 - Entresto will very soon prove to be a blockbuster cardiovascular drug.Cosentyx has the potential to become a blockbuster drug in each of its approved indications.CAR-T therapy, Kymriah, is testimony t
REGN: Canaccord Genuity cuts to Hold http://www.briefing.com/investor/popuppages/articlepopup.aspx?articleId=UD20180221094500 Feb 21, 2018 - Canaccord Genuity issues rating change for REGN
Novavax (NVAX) in Focus: Stock Moves 8.3% Higher http://www.zacks.com/stock/news/292934/novavax-nvax-in-focus-stock-moves-83-higher?cid=CS-ZC-FT-292934 Feb 20, 2018 - The shares of Novavax (NVAX) rose over 8% yesterday.
The Zacks Analyst Blog Highlights: Nordisk, TJX, Cigna, Regeneron and ArcelorMittal http://www.zacks.com/stock/news/292909/the-zacks-analyst-blog-highlights-nordisk-tjx-cigna-regeneron-and-arcelormittal?cid=CS-ZC-FT-292909 Feb 20, 2018 - The Zacks Analyst Blog Highlights: Nordisk, TJX, Cigna, Regeneron and ArcelorMittal
Regeneron Annual Report, Earnings Forecast And Stock Valuation https://seekingalpha.com/article/4148074-regeneron-annual-report-earnings-forecast-stock-valuation?source=feed_sector_healthcare Feb 19, 2018 - Regeneron's earnings and revenue projections are strong.The stock price is currently undervalued.The company's extremely strong financial position.Analyst expectations are rising.
Celgene's Otezla-Colitis Story; Implications For Other Biotechs https://seekingalpha.com/article/4147853-celgenes-otezla-colitis-story-implications-biotechs?source=feed_tag_editors_picks Feb 16, 2018 - CELG put out an optimistically-titled press release regarding a mid-stage clinical trial for its newest blockbuster, Otezla.My interpretation of the data is at variance with that of CELG.I see CELG do

Pages: 123456...55

Page 1>

Related Companies

Name Exchange Price Mkt Cap
SHPG Shire plc NASDAQ $127.08 $38.55B
ZTS Zoetis Inc. NYSE $82.79 $40.17B
VRTX Vertex Pharmaceuticals Incorporated NASDAQ $165.9 $42.12B
ALXN Alexion Pharmaceuticals, Inc. NASDAQ $118.93 $26.36B
MYL Mylan N.V. NASDAQ $41.45 $22.24B
Sector: Health Care > Industry: Major Pharmaceuticals
DeepLinks for Regeneron Pharmaceuticals
REGN - Google Finance https://www.google.com/finance?q=REGN Industry related info and international coverage Summary News
REGN - Bloomberg http://www.bloomberg.com/research/stocks/snapshot/snapshot.asp?ticker=REGN Original news and commentary from Bloomberg Charts Financials with pensions Snapshot Earnings Transactions People Options